WHO GMP · USFDA · ISO 9001 — Laborate's flagship facility for solid oral dosage form manufacturing since 1985.
Established in 1985 as Laborate's founding manufacturing site, the Panipat Formulation Plant — Unit I is the cornerstone of the company's production network. Located in the heart of Haryana's industrial corridor, this facility has grown from a single solid dosage line to an eight-line operation producing approximately 4 million units per day.
The plant specialises in solid oral dosage forms — tablets, capsules, dry syrup powders and liquid orals — serving both the domestic Indian market and regulated export markets in Africa, Southeast Asia and the United States. All operations are performed under WHO GMP and USFDA frameworks, with an integrated NABL-accredited QC laboratory on-site.
With over four decades of continuous operation, Panipat Unit I carries the deepest institutional knowledge in Laborate's network. It serves as the primary site for new product development, scale-up, and technology transfer for the wider facility group.
Eight active manufacturing lines covering solid oral, liquid oral and semi-solid dosage forms across domestic and regulated export markets.
Line 01
Uncoated & Film-Coated Tablets
1,500,000 tablets / shift
Line 02
Uncoated Tablets — Generic & Branded
1,000,000 tablets / shift
Line 03
Aqueous & Organic Film Coating
800,000 tablets / shift
Line 04
Hard Capsules — Sizes 0–5
2,000,000 capsules / shift
Line 05
Dry Powder for Oral Suspension
300,000 bottles / shift
Line 06
Syrups, Suspensions & Solutions
180,000 bottles / shift
Line 07
Alu-Alu & PVC Blister Packs
3,000,000 blisters / shift
Line 08
Track & Trace — US/EU Serialisation
1,500,000 units / shift
Indicative daily production capacity per dosage form across all active shifts. Actual capacity subject to product-specific batch sizes and scheduling.
| Dosage Form | Daily Capacity | Unit | Shifts / Day | Notes |
|---|---|---|---|---|
| Film-Coated Tablets | 3,000,000 | Tablets | 2 | Aqueous film coating, WHO GMP line |
| Hard Gelatin Capsules | 4,000,000 | Capsules | 2 | Sizes 0–5, export & domestic |
| Dry Powder for Oral Suspension | 600,000 | Bottles | 2 | 60ml & 100ml fill formats |
| Liquid Oral (Syrup / Suspension) | 360,000 | Bottles | 2 | 30ml–200ml, child-resistant closure |
| Blister-Packed Solid Dosage | 6,000,000 | Blisters | 2 | Alu-Alu & PVC — domestic and export formats |
All certifications held by this facility are independently audited and maintained on an ongoing basis.
From one line in 1985 to eight lines and 1,200+ employees — the story of Laborate's founding facility.
Panipat Unit I inaugurated as Laborate's founding manufacturing facility. Solid oral dosage form production begins with Line 01 and Line 02.
FoundingFirst WHO GMP certification awarded to Unit I. Laborate begins supplying regulated markets in Africa and Southeast Asia from this facility.
RegulatoryOn-site quality control laboratory receives NABL accreditation under ISO/IEC 17025. Analytical capabilities expanded to support 400+ product registrations.
QualityUnit I receives USFDA pre-approval inspection clearance — enabling Laborate to supply the US regulated market with solid dosage forms.
RegulatoryLines 3–6 commissioned. Tablet, capsule, dry syrup and liquid oral capabilities added. Daily output doubles to 2 million units per day.
ExpansionISO 9001:2008 upgraded to ISO 9001:2015. Automated Alu-Alu blister packaging lines installed. Export packaging capacity reaches 3 million blisters per shift.
UpgradeLines 7–8 commissioned including export serialisation capability. Total capacity reaches ~4 million units per day. Workforce grows to 1,200+ employees.
ExpansionFull compliance achieved with India's revised Schedule M (GMP Norms for Pharmaceutical Plants). Unit I becomes the model reference site for Laborate's network.
ComplianceCurrent regulatory approvals held by this facility. Certificates available on request for audit purposes.
PLT-02
Paonta Sahib, Himachal Pradesh
PLT-03
Karnal, Haryana
PLT-04
Panipat, Haryana
Contact our manufacturing team to arrange a facility audit or discuss CDMO and contract manufacturing requirements.
